Atopic Dermatitis Host and Environment Model: Revisiting Therapeutic Options [PDF]
, 2020 Atopic Dermatitis affects both children and adults and is a serious health concern in many countries. AD is a complex disease with host and environmental factors underlying its pathology. Its treatment is multidimensional reflecting the diverse nature of
Abreu, C +3 more
core +1 more source
Development of Assay for Determining Free IgE Levels in Serum from Patients Treated with Omalizumab
Allergology International, 2014 Background: Omalizumab, a monoclonal anti-IgE antibody, is currently indicated for the treatment of moderate-to-severe allergic asthma. To measure active IgE levels in sera from patients treated with omalizumab, the IgE subfraction in complex with ...
Reiko Ito +9 more
doaj +1 more source
Diagnosis and management of eosinophilic asthma: a US perspective. [PDF]
, 2014 Eosinophilic asthma is now recognized as an important subphenotype of asthma based on the pattern of inflammatory cellular infiltrate in the airway. Eosinophilic asthma can be associated with increased asthma severity, atopy, late-onset disease, and ...
Doherty, Taylor A, Walford, Hannah H
core +1 more source
Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care. [PDF]
, 2015 BACKGROUND: Omalizumab is approved in the UK as add-on treatment for chronic spontaneous urticaria (CSU) in patients with inadequate response to H1-antihistamines. Ciclosporin is an established but unlicensed 3rd line option for CSU.
Ardern-Jones, MR +7 more
core +2 more sources
Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China
World Allergy Organization Journal, 2022 Background: Omalizumab is an effective treatment for chronic spontaneous urticaria (CSU) patients aged ≥12 years, but its efficacy in patients aged
Ao Wang, MD +7 more
doaj +1 more source
Treatment of estrogen-induced dermatitis with omalizumab [PDF]
, 2019 In 1945, Drs Bernhard Zondek and Yehuda Bromberg demonstrated intradermal treatment with estrone and estradiol benzoate induced urticarial lesions in some patients.1 Fifty years later, Shelley et al,2 who introduced the concept of progesterone dermatitis
Baker, William H. +5 more
core +1 more source
Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels : a pilot study [PDF]
, 2018 Background: Administration of the therapeutic anti-IgE antibody omalizumab to patients induces strong increases in IgE antibody levels. Objective: To investigate the effect of intranasal administration of major birch pollen allergen Bet v 1, omalizumab ...
Bischoff +38 more
core +1 more source
Omalizumab rapidly improves angioedema‐related quality of life in adult patients with chronic spontaneous urticaria: X‐ACT study data [PDF]
, 2018 Background: The X‐ACT study aimed to examine the effect of omalizumab treatment on quality of life (QoL) in chronic spontaneous urticaria (CSU) patients with angioedema refractory to high doses of H1‐antihistamines. Methods: In X‐ACT, a phase III, double‐
Barbosa +29 more
core +1 more source
What's new in the diagnosis and management of food allergy in children? [PDF]
, 2013 This article reviews the recent advances in the diagnosis and management of IgE mediated food allergy in children. It will encompass the emerging technology of component testing; moves to standardization of the allergy food challenge; permissive diets ...
Campbell, DE, Turner, PJ
core +1 more source
Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin [PDF]
, 2017 Background. Treatment with omalizumab, a humanized recombinant monoclonal anti-IgE antibody, results in clinical efficacy in patients with Chronic Spontaneous Urticaria (CSU). The mechanism of action of omalizumab in CSU has not been elucidated in detail.
Ashton-Chess, Joanna +12 more
core +1 more source